Ravinder Dhawan - Concepedia

Author

Ravinder Dhawan

Millennium Engineering and Integration (United States)

Also Known As

Dhawan Ravinder, R Dhawan, R. Dhawan, RAVINDER DHAWAN, Ravinder Dhawan, Rohan Dhawan

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Millennium Engineering and Integration (United States)Johnson & Johnson (United States)Analysis Group (United States)Dana-Farber Cancer Institute Janssen (United States)

About

Ravinder Dhawan is an author at Millennium Engineering and Integration (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	234
2	Health Sciences	2	2	62
3	Public Health	2	2	68
4	Business	1	1	76
5	Biostatistics	1	1	34

Ravinder Dhawan

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The prevalence of nocturia and its effect on health‐related quality of life and sleep in a community sample in the USA Karin S. Coyne, Zhiyuan Zhou, Samir Bhattacharyya, British Journal of Urology	2003	332
Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma Dominique Dubois, Ravinder Dhawan, Helgi van de Velde, Journal of Clinical Oncology	2006	99
Exchange rate volatility and Pakistan's exports to the developed world, 1974–85 Ramesh Kumar, Ravinder Dhawan World Development EconomicsDeveloped WorldInternational FinanceTradeExchange Rate Movement	1991	76
Health‐related quality of life in elderly, newly diagnosed multiple myeloma patients treated with <scp>VMP</scp> vs. <scp>MP</scp>: results from the <scp>VISTA</scp> trial Michel Delforge, Ravinder Dhawan, Don Robinson, European Journal Of Haematology	2012	70
Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study Stephanie J. Lee, Paul G. Richardson, Pieter Sonneveld, British Journal of Haematology	2008	65
A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Mark J. Atkinson, William C. Stewart, Joel Fain, Health and Quality of Life Outcomes	2003	63
The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment Louis P. Garrison, Si-Tien Wang, Hui Huang, The Oncologist	2013	60
Utility of Cancer Value Frameworks for Patients, Payers, and Physicians Amitabh Chandra, Jason Shafrin, Ravinder Dhawan JAMA Cancer ManagementOtorhinolaryngologyCancer RegistrationSurgeryHealth Care Finance	2016	58
Assessing Health Utilities in Schizophrenia Lakshmi N.P. Voruganti, A. George Awad, L. Kola Oyewumi, PharmacoEconomics Psychiatric EvaluationPsychiatryPsychotic DisorderSchizophreniaClinical Psychiatry	2000	40
Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis Muriel Viala, Asha Bhakar, Christine de la Loge, Journal of Clinical Epidemiology Hematological MalignancyPatient-reported OutcomesMedicinePrognosisMultiple Myeloma	2007	34

Page 1